ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.5166A>T (p.Glu1722Asp)

dbSNP: rs1597830174
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001245761 SCV001419070 uncertain significance Neurofibromatosis, type 1 2019-10-12 criteria provided, single submitter clinical testing This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The aspartic acid amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with NF1-related conditions. This sequence change replaces glutamic acid with aspartic acid at codon 1701 of the NF1 protein (p.Glu1701Asp). The glutamic acid residue is weakly conserved and there is a small physicochemical difference between glutamic acid and aspartic acid.
Ambry Genetics RCV002348836 SCV002645817 uncertain significance Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2022-05-12 criteria provided, single submitter clinical testing The p.E1701D variant (also known as c.5103A>T), located in coding exon 36 of the NF1 gene, results from an A to T substitution at nucleotide position 5103. The glutamic acid at codon 1701 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.